39 results on '"Baca, Yasmine"'
Search Results
2. Unlocking therapeutic potential: IL-1β as a target in non-small cell lung cancer with oncogenic mutations—Prognostic and predictive insights.
3. Molecular differences with therapeutic implications in early-onset compared to average-onset cholangiocarcinoma.
4. Characterization of the cachexia pathway in pancreatic ductal adenocarcinoma.
5. LMTK3 gene expression and the molecular landscape of colorectal cancer (CRC).
6. Genomics and transcriptomics of pancreatic adenosquamous carcinoma.
7. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer
8. The role of gene expression of CDC37 in colorectal cancer (CRC).
9. Molecular correlates of DSCR1 expression in colorectal cancer (CRC).
10. Beyond CPS for PD-L1 scoring: Genetic alterations that impact efficacy of immunotherapy in hepatocellular carcinoma (HCC).
11. Prognostic indicators of KRAS G12X mutations in pancreatic cancer.
12. Comparative analysis of the molecular profile and tumor immune microenvironment (TIME) of human epidermal growth factor receptor 2 (HER2) low (L)- versus high (H)-expressing gastroesophageal cancers (GEC).
13. The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC).
14. CXCR4 overexpression: An indicator of poor survival and predictor of response to immunotherapy in patients with metastatic colorectal cancer.
15. Acquired EGFR-resistant mutations in non–small cell lung cancer (NSCLC).
16. Comprehensive profiling of clock genes expression in colorectal cancer (CRC).
17. Characterization of TIM3 and its ligands in colorectal cancer.
18. DEFB1 gene expression and the molecular landscape of colorectal cancer (CRC).
19. Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors.
20. Molecular correlates of MAEA expression in colorectal cancer (CRC).
21. Impact of somatic SWI/SNF alterations on the genomic landscape of pancreatic ductal adenocarcinoma and response to PARP and immune checkpoint inhibitor therapy.
22. Multiomic characterization to reveal a distinct molecular landscape in young-onset pancreatic cancer.
23. Comparative molecular profiling of pancreatic ductal adenocarcinoma (PDAC) of the head (H) versus body/tail (B/T) and the tumor immune microenvironment (TIME).
24. High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.
25. Globo H expression in metastatic colorectal cancer (CRC).
26. Comprehensive characterization of neurotransmitters and neuronal signaling (NT) pathway alterations in colorectal cancer (CRC).
27. STK11/TP53 co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.
28. Prognostic impact of XPO1 mutations in metastatic non-small cell lung cancer (NSCLC).
29. Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.
30. Association of high gene expression levels of ARF6 with the immune microenvironment and prediction of poor outcomes.
31. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas.
32. Molecular characterization of pancreatic cancers as seen in the SLUG gene revealing cancer progression.
33. Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).
34. Comprehensive gene expression analysis of IDH1/2 mutant biliary cancers (BC).
35. Is there a genomic fingerprint of Radon (Rn)-induced lung cancer (LC)? Comparison of genomic alterations in LC specimens from high and low Rn zones.
36. Correlation of tumor mutational burden (TMB) with CDKN2A and TP53 mutation in HPV-negative head and neck squamous cell carcinoma (HNSCC).
37. Molecular characterization of appendiceal goblet cell carcinoid.
38. Molecular landscape of gastric cancer (GC) harboring mutations of histone methyltransferases.
39. Comprehensive molecular profiling of IDH1/2 mutant biliary cancers (BC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.